in a variety of other rheumatic diseases. Risks of carcinogenesis and leukaemogenesis are real, and should be compared to those from cytotoxic therapy (Casciato & Scoci 1979) . Bone marrow toxicity is unavoidable and may be potentiated by previous cytotoxic therapy or irradiation, and this may be a life-threatening complication (Morgan et al. 1985) if caution in planning dosage is not observed.
Anti-Jo-l-antibody, an autoantibody directed against histidyl-t-RNA synthetase (Matthews & Bernstein 1983) (Figure 1 ). Biopsy of this revealed it to be a malignant fibrous histiocytoma (MFH) and he was admitted for disarticulation of the stump through the hip joint and excision and biopsy of the mass on the left trunk. This latter proved also to be an MFH. He made a good recovery from this operation but seven months later a chest X-ray revealed a mass in the right upper lobe which was presumed to be a metastasis. He Danese et al. 1967) .
A review of the literature has not revealed any cases where the tumours would now be classified as MFH, and our case appears unique. These tumours have a variable histological appearance and prediction of clinical behaviour is difficult, but 35% recur within 10 months of surgery and in one series 54% of patients died within two years (Hajdu 1979) .
Theories to account for the development of lymphangiosarcomas include (1) the concept that the affected limb is an immunologically privileged site because of the loss of afferent lymphatics (Lozewski et al. 1978) , and (2) the escape from the normal regulatory mechanisms of the growth of obstructed lymphatics (Danese et al. 1967 ); alternatively we suggest there may be an accumulation of carcinogens in the lymphatic fluid.
In our case, the tumours were all malignant fibrous histiocytomas; these arise from primitive mesenchymal cells, which presumably also proliferate in lymphoedematous limbs and may be subject to the same factors potentially inducing neoplasia as vascular endothelium.
